Business Context and Reporting Period
Company: Bright Minds Biosciences Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: February 2026 (Notice of Annual General Meeting)
Key Event: Notification of the Annual General Meeting of Shareholders scheduled for March 31, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a procedural notice regarding shareholder meetings and incorporates by reference prior registration statements (Form F-3) rather than presenting standalone financial results for the period.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this specific filing. The document focuses on corporate governance procedures and the incorporation of previous registration statements filed in February 2025 and August 2025.
Guidance, Outlook, and Risks
Management Commentary: The filing includes a Management Information Circular (Exhibit 99.3) and a Proxy Card (Exhibit 99.4) related to the upcoming Annual General Meeting.
Risks and Contingencies: No specific risks or contingencies are detailed in the text of this Form 6-K summary. Investors are directed to the incorporated registration statements for broader disclosures.
Key Facts for Investor Verification
- Verify the date and agenda of the Annual General Meeting scheduled for March 31, 2026.
- Review the incorporated Form F-3 registration statements (File Nos. 333-284694 and 333-289851) for detailed financial data and risk factors.
- Confirm the details of the Notice and Access Notification to Shareholders (Exhibit 99.2).
- Note that this filing was signed by Ryan Cheung, Chief Financial Officer, on June 3, 2026.